Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
Top Cited Papers
- 21 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 43 (8), 691-698
- https://doi.org/10.1007/s40264-020-00976-7
Abstract
The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.Keywords
This publication has 66 references indexed in Scilit:
- Azithromycin and the Risk of Cardiovascular DeathThe New England Journal of Medicine, 2012
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Antimicrobials and the Risk of Torsades de PointesDrug Safety, 2010
- Azithromycin induces anti-viral responses in bronchial epithelial cellsEuropean Respiratory Journal, 2010
- Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelProceedings of the National Academy of Sciences of the United States of America, 2008
- Azithromycin‐Induced Torsade De PointesPacing and Clinical Electrophysiology, 2007
- No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic‐AV blockBritish Journal of Pharmacology, 2006
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarctionThe American Journal of Cardiology, 1988
- Clinical classification of cardiac deaths.Circulation, 1982